Our Team

Each Partner brings extensive industry knowledge, unrivaled relationships and substantial deal experience, resulting in a team of the industry's most sought after advisors

Joshua D. Thornton

Josh Thornton is a founding member of the Healthcare practice at Centerview Partners.  He is an experienced advisor to senior management teams and boards of public and private life sciences companies. Over the course of his career he has engaged with life sciences clients across biopharma, medical devices, diagnostics and tools on a broad range of complex strategic and financial issues and transactions, including mergers, acquisitions, divestitures, partnerships, defense, and debt and equity financings.

Mr. Thornton’s recent notable transactions include MyoKardia’s $13.1 billion sale to Bristol Myers Squibb, AveXis’ $8.7bn sale to Novartis, Momenta’s $6.5bn sale to Johnson & Johnson, Principia’s $3.7bn sale to Sanofi, Audentes Therapeutics’ $3.0 billion sale to Astellas Pharma and Portola Pharmaceuticals’ $1.6bn sale to Alexion Pharmaceuticals.

Other notable transactions include Pfizer’s $68 billion acquisition of Wyeth, InterMune’s $8.9 billion sale to Roche, Receptos’ $7.8 billion sale to Celgene, OSI Pharmaceuticals’ $4.0 billion sale to Astellas Pharma, Thoratec’s $3.7 billion sale to St. Jude Medical, Avanir’s $3.5 billion sale to Otsuka, Biogen Idec’s $3.25+ billion acquisition of full rights and control of Tysabri from Elan, Pacific Biosciences’ $1.3 billion sale to Illumina, MAP Pharmaceuticals’ $958 million sale to Allergan, Bioverativ’s acquisition of True North Therapeutics for up to $825mm, Haemonetics’ $551 million acquisition of assets from Pall Corporation, XenoPort’s $457mm sale to Arbor Pharmaceuticals, Ultragenyx’s $151mm acquisition of Dimension Therapeutics, Dendreon Corporation’s sale of a royalty interest to CPPIB, and Cytokinetics’s sale of a royalty interest to Royalty Pharma.

Mr. Thornton joined Centerview in 2009 from Merrill Lynch where he worked in the Mergers & Acquisitions Group. He holds an M.B.A. from the Stern School of Business at New York University and a B.A. in Economics/East Asian Studies from Wesleyan University.
Centerview Partners takes a “One Firm” approach to deliver unmatched intellectual capital and integrity to all of our clients. We have industry-leading expertise in:

Centerview is honored to partner with leading charitable organizations in active support of our charities:

  • Arts Connection
  • NY Cares
  • Bottomless Closet
Announced: Q3 2021
Value: $1.9 billion
Status: Pending

Exclusive financial advisor to Sanofi on its acquisition of Kadmon Holdings, Inc
View All
New York

Centerview Partners LLC

31 West 52nd Street

22nd Floor

New York, New York 10019

(212) 380-2650 | Tel
(212) 380-2651 | Fax

Centerview Partners UK LLP

100 Pall Mall

3rd Floor

London SW1Y 5NQ

02074099700 | Tel
02074099704 | Fax

Centerview Partners France SCS

16 Avenue Matignon

4th Floor

Paris 75008

0180200620 | Tel
0180200621 | Fax
Palo Alto

Centerview Partners LLC

600 Ramona St.

Suite 300

Palo Alto, California 94301

(650) 822-5800 | Tel
(650) 822-5801 | Fax
San Francisco

Centerview Partners LLC

555 California Street

Suite 4300

San Francisco, California 94104

(415) 400-0900 | Tel
(415) 400-0901 | Fax


Centerview Partners LLC

Los Angeles

Centerview Partners LLC

Copyright © 2008 - 2021 Centerview Partners Holdings LP. All Rights Reserved. | Privacy and Other Notices

Centerview Partners LLC, member SIPC